BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Adipose tissue
,
Neocentromeres
,
Rosiglitazone
,
rs3825942
,
IGF1
,
Arthritis
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
EF- Tu
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for EF- Tu
Explore Curated Studies Results
Literature
Most Relevant Literature
Fitness benefits of a synonymous substitution in an ancient EF-Tu gene depend on the genetic backgro…
A beneficial synonymous substitution in EF-Tu is contingent on genetic background.
Ribosomal protein S18 acetyltransferase RimI is responsible for the acetylation of elongation factor…
Cell surface-associated protein elongation factor Tu interacts with fibronectin mediating the adhesi…
Expression of elongation factor (EF)-Tu is correlated with prognosis of gastric adenocarcinomas.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participan…
Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants …
Prospective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ